Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01954693
Other study ID # SPON803-10
Secondary ID 2011-004854-25
Status Active, not recruiting
Phase Phase 2
First received September 5, 2013
Last updated January 29, 2018
Start date June 2012
Est. completion date August 6, 2018

Study information

Verified date January 2018
Source Cardiff University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single centre, two-arm, individually randomised, Phase II, double- blind, placebo-controlled trial of RAD001 (Everolimus) versus placebo in the treatment of neurocognitive problems in patients with tuberous sclerosis (TSC). The IMP is a licensed medicine in this patient group but for a different target of effect. The current trial is a proof of principle study for memory and executive function outcomes.

Following an eligibility visit, patients will be scheduled for baseline visit and randomization. They will then be followed up for 6 months undergoing both safety and neurocognitive assessments whilst taking either the placebo or study drug.

48 patients aged 16 to 60 years with tuberous sclerosis (TSC) who have IQ > 60 and a significant deficit in one or more primary outcome measures will be randomly allocated in a ratio of 2:1 to either RAD001 (Everolimus) or Placebo.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 48
Est. completion date August 6, 2018
Est. primary completion date August 6, 2018
Accepts healthy volunteers No
Gender All
Age group 16 Years to 60 Years
Eligibility Inclusion Criteria:

1. Definite TSC by current clinical criteria (28);

2. Male or female aged 16 to 60 yrs;

3. IQ over 60 by Wechsler Abbreviated Scales of Intelligence (WASI) and able to participate in direct neuropsychological tests;

4. A score falling on, or below, the 5th percentile (approximately equivalent to -1.5 SD) in one or more of the primary outcome measures:

5. Calculated GFR > 60ml/min/1.73m2 except in case of renal impairment associated with TSC complicating kidneys, where a calculated GFR should be =30ml/min/1.73m2;

6. INR 1.5 or less (anticoagulation permitted if target INR on stable dose of warfarin or LMW heparin for > 2 weeks at time of randomisation) ;

7. Adequate liver function as shown by: serum bilirubin less than or equal to 1.5 x ULN, ALT and AST less than or equal to 2.5 x ULN;

8. If sexually active - negative pregnancy test in females at the time of informed consent, contraception for males and pre-menopausal females on study);

9. Seizure free or stable seizures as defined by no change in type of AEDs in 6 months prior to full recruitment and randomization at baseline. Doses of drugs may have been changed in the 6 months prior to recruitment;

10. Hepatitis B surface antigen negative, Hepatitis C antibody negative.

11. All patients must be able to communicate well with the investigator, to understand and comply with the requirements of the study, understand and sign the written informed consent;

12. Female patients of childbearing potential must be prepared to use two acceptable methods of contraception, (e.g., intra-uterine device plus condom, spermicidal gel plus condom, diaphragm plus condom, etc.), from the time of screening.

Exclusion Criteria:

1. Prior treatment with an mTOR inhibitor;

2. Investigational agent <30 days prior to randomisation;

3. Surgery in last 2 months;

4. Previous brain neurosurgery;

5. Significant haematological abnormality i.e. haemoglobin < 8g/dL, platelets <80,000/mm3, absolute neutrophil count < 1000/mm3);

6. Urine protein/creatinine >0.02g/mmol except in case of renal impairment associated with TSC complication of kidneys, where urine protein/creatinine ratio should be >0.1g/mmol for exclusion;

7. Serum creatinine > 1.5 x ULN except in case of renal impairment associated with TSC complication of kidneys, where serum creatinine should be >300µmol/L for exclusion;

8. Uncontrolled hyperlipidaemia (fasting cholesterol > 300mg/dL or >7.75 mmol/L and fasting triglycerides >2.5 x ULN, or diabetes with fasting serum glucose > 1.5 x ULN;

9. History of myocardial infarction, angina or stroke related to atherosclerosis, or any other significant cardiac disease, HIV seropositivity, organ transplant, malignancy other than squamous or basal cell skin cancer;

10. lymphangioleiomyomatosis with FEV1 <70% of predicted, or any other restrictive pulmonary disease;

11. Bleeding diathesis or on oral anti-vitamin K medication other than low dose warfarin;

12. Pregnancy/lactation;

13. Live vaccine required during trial;

14. Use of strong inhibitor of CYP3AE;

15. Use of strong inducer of CYP3AE except for anti epileptic drugs;

16. Intercurrent infection at time of randomisation;

17. Inability to complete study materials (outcome measures) in English;

18. History of significant trauma-related cognitive deficit;

19. Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of Everolimus (e.g. pancreatic insufficiency);

20. Known sensitivity to Everolimus or other Rapamycin analogues or to its excipients;

21. Inability to attend scheduled visits.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo
5mg daily administered for 6 months as two oral 2.5 mg tablets once daily.
Everolimus (RAD001)
5mg daily administered for 6 months as two oral 2.5 mg tablets once daily

Locations

Country Name City State
United Kingdom Cardiff University Cardiff

Sponsors (2)

Lead Sponsor Collaborator
Cardiff University Novartis

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Wechsler Abbreviated Scale of Intelligence (WASI) (4 subtests) Eligibility visit screening measure Eligibility visit
Other Edinburgh Handedness Test Eligibility visit screening measures Eligibility visit
Primary List Learning test (from the BIRT Memory and Information Processing Battery) 6 months
Primary Complex Figure test (from the BIRT Memory and Information Processing Battery) 6 months
Primary CANTAB - Stockings of Cambridge (SOC) 6 months
Primary CANTAB - Spatial Working Memory (SWM) 6 months
Primary Telephone search dual task (from the Test of Everyday Attention) 6 months
Secondary CANTAB - Rapid Visual Information Processing Battery (RVIP) 6 months
Secondary CANTAB - Spatial Span (SSP) 6 months
Secondary CANTAB - Attentional Set-shifting (IDED) 6 month
Secondary Verbal Fluency /Controlled Oral Word Association Test (COWAT) 6 months
Secondary Cancellation task 6 months
Secondary Symptom Checklist 90R (SCL-90R) 6 months
Secondary Quality of Life in Epilepsy (QOLIE) 6 months
Secondary Liverpool Seizure Severity Scale (LSSS) 6 months
Secondary Vineland Adaptive Behavior Scales-II (VABS-II) (survey form) 6 months
Secondary Social Responsiveness Scale - Adult version (SRS-A) 6 months
Secondary Social communication questionnaire (SCQ) 6 months
Secondary National Adult Reading Test (NART) 6 months
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06139172 - Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities N/A
Recruiting NCT00001532 - Role of Genetic Factors in the Development of Lung Disease
Completed NCT00552955 - Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women
Recruiting NCT03422367 - JASPER Early Intervention for Tuberous Sclerosis N/A
Not yet recruiting NCT06081348 - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Phase 2
Unknown status NCT00490789 - Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM Phase 2
Recruiting NCT04463316 - GROWing Up With Rare GENEtic Syndromes
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Enrolling by invitation NCT03836300 - Parent and Infant Inter(X)Action Intervention (PIXI) N/A
Completed NCT02104011 - Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers Phase 2
Recruiting NCT02461459 - Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
Completed NCT01526356 - Topical Rapamycin to Erase Angiofibromas in TSC Phase 2
Withdrawn NCT03254680 - Turmeric as Treatment in Epilepsy N/A
Terminated NCT01092208 - Studies of Autistic Patients: Gene Networks and Clinical Subtypes
Completed NCT03826628 - Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex Phase 2/Phase 3
Completed NCT00989742 - Doxycycline In Lymphangioleiomyomatosis (LAM) Phase 4
Recruiting NCT05286632 - KidneYou - Innovative Digital Therapy N/A
Withdrawn NCT04344626 - Use of a Tonometer to Identify Epileptogenic Lesions During Pediatric Epilepsy Surgery N/A
Recruiting NCT05199402 - Clinical Trial Data Set Re-use With Statistical Methodologies Tailored for Clinical Trials in Rare Diseases
Recruiting NCT00001975 - Study of Skin Tumors in Tuberous Sclerosis